Price$2.53+0.00 (+0.00%)
2025-07-032025-10-06
Latest news
25 items- SECTrevena Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - TREVENA INC (0001429560) (Filer)
- SECSEC Form 25-NSE filed by Trevena Inc.25-NSE - TREVENA INC (0001429560) (Subject)
- SECSEC Form NT 10-K filed by Trevena Inc.NT 10-K - TREVENA INC (0001429560) (Filer)
- SECTrevena Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - TREVENA INC (0001429560) (Filer)
- SECTrevena Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - TREVENA INC (0001429560) (Filer)
- INSIDERNew insider Sutton Katrine claimed ownership of 942 shares (SEC Form 3)3 - TREVENA INC (0001429560) (Issuer)
- SECSEC Form RW filed by Trevena Inc.RW - TREVENA INC (0001429560) (Filer)
- SECTrevena Inc. filed SEC Form 8-K: Leadership Update8-K - TREVENA INC (0001429560) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Trevena Inc.SC 13G/A - TREVENA INC (0001429560) (Subject)
- SECSEC Form 10-Q filed by Trevena Inc.10-Q - TREVENA INC (0001429560) (Filer)
- SECTrevena Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - TREVENA INC (0001429560) (Filer)
- PRTrevena Reports Third Quarter 2024 Results and Provides Business UpdateCHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates $2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a non-dilutive, $2 million tranche in connection with an amendment (the "Amendment") to its existing ex-US royalty financing with R-Bridge Healthcare Fund ("R-Bridge"). The Compa
- INSIDERActing CMO Demitrack Mark covered exercise/tax liability with 885 shares, decreasing direct ownership by 7% to 11,363 units (SEC Form 4)4 - TREVENA INC (0001429560) (Issuer)
- INSIDERActing COO and CFO Shin Barry covered exercise/tax liability with 806 shares, decreasing direct ownership by 7% to 11,543 units (SEC Form 4)4 - TREVENA INC (0001429560) (Issuer)
- INSIDERActing CEO Bourdow Carrie L. covered exercise/tax liability with 1,822 shares, decreasing direct ownership by 7% to 23,894 units (SEC Form 4)4 - TREVENA INC (0001429560) (Issuer)
- SECTrevena Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - TREVENA INC (0001429560) (Filer)
- SECTrevena Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TREVENA INC (0001429560) (Filer)
- PRTrevena Announces Receipt of Nasdaq Delisting NotificationCHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Company until October 2, 2024, to regain comp
- 13D/GSEC Form SC 13G filed by Trevena Inc.SC 13G - TREVENA INC (0001429560) (Subject)
- INSIDERSVP, Chief Business Officer Yoder Robert T covered exercise/tax liability with 487 shares, decreasing direct ownership by 8% to 5,868 units (SEC Form 4)4 - TREVENA INC (0001429560) (Issuer)
- INSIDERSVP, CFO Shin Barry covered exercise/tax liability with 3 shares, decreasing direct ownership by 0.02% to 12,349 units (SEC Form 4)4 - TREVENA INC (0001429560) (Issuer)
- SECTrevena Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - TREVENA INC (0001429560) (Filer)
- SECTrevena Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - TREVENA INC (0001429560) (Filer)
- PRTrevena Announces Reverse Stock SplitCHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on Tuesday, August 13, 2024. Trevena's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "TRVN" and will begin trading on a split-adjusted basis when the market opens on Tu
- SECSEC Form 10-Q filed by Trevena Inc.10-Q - TREVENA INC (0001429560) (Filer)
TRVN FAQ
6 questionsWhat does Trevena Inc. do?
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for...Where does TRVN stock trade?
Trevena Inc. (TRVN) is listed on NASDAQ.What sector and industry is TRVN in?
Trevena Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Trevena Inc. go public?
Trevena Inc. (TRVN) completed its IPO in 2014.What companies are similar to TRVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TRVN side-by-side with any of them on Quantisnow.How can I track TRVN on Quantisnow?
Quantisnow aggregates Trevena Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRVN to receive live email and push alerts on every new disclosure.